About us
APIM Therapeutics is a clinical-stage oncology company developing first-in-class PCNA-targeting therapeutics.
The Company is developing first-in-class PCNA-targeting therapeutics that disrupt cellular stress responses and overcome cancer treatment resistance. ATX-101, its lead candidate, has been evaluated in Phase Ib and Phase II clinical studies in ovarian cancer and soft tissue sarcoma.
Drug Pipeline
APIM Therapeutics is developing a pipeline of peptide therapeutics targeting PCNA-dependent stress responses in cancer cells.
Media Center
New patents protecting ATX-101 for sarcoma have been granted in major markets; see our News section for more details.
Business Development
Our vision is to develop first-in-class PCNA-targeting therapeutics, both as single agents and in combination with existing cancer therapies, to address significant unmet medical needs.